Celgene Announces Phase II Study Evaluating Clinical Benefits of ABRAXANE Plus Gemcitabine and Bevacizumab as First-Line Treatment in Patients with Metastatic Breast Cancer Presented at ASCO

Celgene International Sàrl CELG today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL. In the study, patients eligible for first-line chemotherapy were given ABRAXANE (125 mg/m2), followed by gemcitabine (1000 mg/m2) on days 1 and 8, followed by bevacizumab (15 mg/kg) on day 1 of each 21 day cycle. Forty-eight patients were evaluable for the study.